Products
Healthy nucleic acid extraction pcr machine CE-certification gene test kit gene fusion genotyping sensitive detection kit
Healthy nucleic acid extraction pcr machine CE-certification gene test kit gene fusion genotyping sensitive detection kit
Healthy nucleic acid extraction pcr machine CE-certification gene test kit gene fusion genotyping sensitive detection kit
Healthy nucleic acid extraction pcr machine CE-certification gene test kit gene fusion genotyping sensitive detection kit
Healthy nucleic acid extraction pcr machine CE-certification gene test kit gene fusion genotyping sensitive detection kit
Healthy nucleic acid extraction pcr machine CE-certification gene test kit gene fusion genotyping sensitive detection kit
Healthy nucleic acid extraction pcr machine CE-certification gene test kit gene fusion genotyping sensitive detection kit
Healthy nucleic acid extraction pcr machine CE-certification gene test kit gene fusion genotyping sensitive detection kit

Healthy nucleic acid extraction pcr machine CE-certification gene test kit gene fusion genotyping sensitive detection kit

FOB Reference Price: Get Latest Price
≥200 Boxes
US $1370
Free Inquiry
Customized Request
  • Product Details
  • {{item.text}}

Quick Details

Model Number:
T0725
Place of Origin:
Hubei, China
Product name:
HemaFus BCR-ABL1(P210) Fusion Gene High Sensitivity Detection Kit
Certificate:
CE
Specification:
48 Tests/Kit
OEM/ODM:
accept

Quick Details

Warranty:
1 Year
After-sale Service:
Online technical support
Brand Name:
Healthy
Model Number:
T0725
Place of Origin:
Hubei, China
Product name:
HemaFus BCR-ABL1(P210) Fusion Gene High Sensitivity Detection Kit
Certificate:
CE
Specification:
48 Tests/Kit
OEM/ODM:
accept
Overview

Background

Philadelphia chromosome (Ph), characterized by the translocation t(9;22) (q34;q11) and BCR/ABL1 fusion gene are noted in over 95% of chronic myelocytic leukemia (CML) patients (Figure 1). The BCR-ABL fusion gene is identified in 25%-30% of adult ALL cases, 2%-10% of childhood ALL cases, as well as in less than 2% of AML (lymphoma and myeloma) cases. Meanwhile, few patients have simple variant, complex or masked Ph translocation. Three breakpoint cluster regions -- major (M-bcr), minor (m-bcr), and μ (μ-bcr) -- have been characterized to date. And ABL genes have a break in intron 1 or 2.


Because of different breakpoints, BCR-ABL fusion gene and its mRNA and protein products are diverse. According to different breakpoints of BCR gene, there are several main types of BCR-ABL fusion gene (Figure 2): 1) In typical CML, the majority of fusion genes are broken and fused in the major-bcr (M-bcr) region. The resulting BCR-ABL fusion mRNA is transcribed from either b3a2 or b2a2 and encodes P210 fusion protein, which is the root cause of phenotypic abnormalities in most chronic phase CML. 2) When the breakpoint of BCR gene occurs in a 54.4 kb upstream intron, also known as m-bcr region, hybrid mRNA with e1a2 linker is produced, which encodes P190 fusion protein. 3) The BCR breakpoint also occurs in the M-bcr downstream region, namely μ-bcr, to produce e19a2 fusion, which encodes P230 fusion protein.
Ph chromosome or BCR-ABL1 (b2a2 and b3a2) have emerged as the main diagnostic criteria for CML, while e1a2 mainly appears in ALL. In CML patients, the typical BCR-ABL1 transcript subtypes are b3a2 (55%) and b2a2 (40%); due to different splicing, simultaneous expression of both b3a2 and b2a2 occurs in 5% of CML patients. Moreover, the BCR-ABL e19a2 fusion gene is observed in very few Ph+ CML patients. Subtype P210 can be found in 30%–50% of adult Ph+ ALL patients and 20%–30% of childhood Ph+ ALL patients; BCR-ABL fusion gene subtype is P190 in 60% of Ph+ ALL patients. Tyrosine kinase inhibitors (TKIs), such as imatinib, have been utilized as first-line drug in CML patients with positive BCR-ABL1 to achieve a 10-year survival rate of 85%–90%. Second-generation TKIs, such as nilotinib and dasatinib, not only lead to faster and deeper molecular responses in the first-line treatment of CML, but have also become the preferred first-line treatment option for CML patients. ALL patients with positive BCR-ABL have a poor prognosis with a 5-year survival rate of < 20%. Therefore, these patients require bone marrow transplantation after remission.
Product Description

Other detection kits about gene fushion:
Model
Product name
Strength
Price
J0334
24 Tests/Kit
$14/Test, $334/Kit
J0388
24 Tests/Kit
$21/Test, $500/Kit
T0296
24 Tests/Kit
$17/Test, $400/Kit
T0725
48 Tests/Kit
$28/Test, $1334/Kit
T0295
24 Tests/Kit
$17/Test, $400/Kit
J0366
24 Tests/Kit
$14/Test, $334/Kit
T0305
24 Tests/Kit
$17/Test, $400/Kit
T0306
24 Tests/Kit
$17/Test, $400/Kit
T0307
24 Tests/Kit
$17/Test, $400/Kit
T0325
24 Tests/Kit
$14/Test, $334/Kit
T0294
24 Tests/Kit
$17/Test, $400/Kit
J0335
24 Tests/Kit
$14/Test, $334/Kit
T0298
24 Tests/Kit
$17/Test, $400/Kit
J0354
24 Tests/Kit
$14/Test, $334/Kit
T0768
24 Tests/Kit
$17/Test, $400/Kit
J0369
24 Tests/Kit
$14/Test, $334/Kit
T0309
24 Tests/Kit
$17/Test, $400/Kit
J0340
24 Tests/Kit
$14/Test, $334/Kit
T0299
24 Tests/Kit
$17/Test, $400/Kit
T0310
24 Tests/Kit
$17/Test, $400/Kit
J0683
24 Tests/Kit
$49/Test, $1167/Kit
T0954
24 Tests/Kit
$17/Test, $400/Kit
T0297
24 Tests/Kit
$20/Test, $467/Kit
T0308
24 Tests/Kit
$23/Test, $534/Kit
T0690
24 Tests/Kit
$62.5/Test, $1500/Kit
APP
Post My RFQ
WhatsApp
+86-17326049340